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Multifunctional theranostic gold nanoparticles
for targeted CT imaging and photothermal
therapy
Taeyjuana Currya, Raoul Kopelmana, Malka Shilob and Rachela Popovtzerb*
Gold nanoparticles have emerged as some of the most extensively utilized nanoplatforms for the diagnosis,
imaging, monitoring and treatment of malignant diseases. In particular, in computed tomography (CT) imaging
and in therapy (PTT), the exploitation of the various, advantageous properties of gold nanoparticles have resulted
in numerous advances in each of these ﬁelds. The purpose of this review is to assess the status of
gold-nanoparticle mediated CT and PTT, highlight several promising outcomes and motivate the combination of
these two functionalities in the same nanoparticle platform. The given examples of research based advances and
the encouraging results of in vitro and in vivo studies provide much excitement and promise for future theranostic
(therapy +diagnostic) clinical applications, as well as for image-guided therapy and/or surgery, and their monitor-
ing. Copyright © 2014 John Wiley & Sons, Ltd.
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1. INTRODUCTION
One of the major aims in nanomedicine is the ability to perform
multiple functions using the same nanovehicle, that is, the ability
to target, image, diagnose and monitor cells using only a single
nanoparticle. The unique physical and optical properties of gold
nanoparticles, as well as the ability to attach multiple types of
ligands to their surfaces, has led to varying schemes for
developing multifunctional gold nanoparticles, with multiple
capabilities within a single platform (1–3). Compared with other
methods, treatment plans involving the use of multifunctional
nanoparticles hold the promise of more acurately targeted
treatment, with a higher likelihood of a successful outcome. So
far, gold nanoparticles (GNPs) have been utilized for drug
delivery, phototherapy and as a contrast-enhancing agent for
optical, computed tomography (CT), Raman, X-ray, diffusion
reﬂection and photoacoustic imaging applications (1,4–14). It is
this multipronged approach on which many studies have been
anchored, since it addresses many issues usually associated with
the most aggressive aspects of disease, including multidrug
resistance and recurrence of tumors.
This review addresses the potential simultaneous utilization of
GNPs for diagnostics (CT being the most common medical
imaging method) and for the emerging and highly promising
treatment by photothermal therapy (PTT), thus providing a
classical example for nanoparticle-based ‘theranostics’ (combined
therapy and diagnostics).
In the following sections we ﬁrst describe the basic design
principles that enable gold nanoparticles to be utilized both
as targeted CT contrast agents and as targeted PTT enablers.
Next, we review recent CT imaging studies, studies in which
gold nanoparticles expanded the role of the CT beyond its
present structural imaging capabilities, endowing it with func-
tional and molecular-based imaging capabilities as well. Finally,
gold nanoparticle-mediated PTT will be described, focusing on
targeting the cell’s nucleus. In the case of CT imaging contrast
enhancement, GNPs attenuate X-rays more efﬁciently than the
sometimes used iodine by orders of magnitude. This is due
not only to the much stronger attenuation per atom (gold vs
iodine) but also to the large number of atoms per gold
nanoparticle (e.g. spherical 20 nm particle, containing
~2 × 105 gold atoms, which is 8 × 10-14 mg gold per nanoparti-
cle). Furthermore, it is easier to attach targeting moieties, such
as peptides or antibodies, to GNPs, and there is a large
targeting efﬁciency beneﬁt owing to the multivalency
targeting effect, that is, the large number of targeting ligands
per GNP. Furthermore, there is better body tolerance towards
GNPs compared with iodine. Finally, in case of theranostic
treatment, that is, combined use of GNPs for both imaging
and therapy, there is an obvious conservation of dose
advantage. In the case of photothermal therapy, GNPs are
advantageous because of their ability to strongly absorb light
(orders of magnitude higher than organic dye molecules) (4),
and then convert the absorbed light into heat via nonradiative
processes. This process occurs on a time scale on the order of
picoseconds, leading to intense localized heating and irrepara-
ble damage to the cell (15,16).
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2. GOLD NANOPARTICLES: IDEAL CT
CONTRAST AGENTS AND PTT MEDIATORS
Currently, CT is one of the leading radiology technologies applied in
the ﬁeld of biomedical imaging. CT provides superior visualization of
bone structures owing to the inherent contrast between electron-
dense bones and the more permeable surrounding soft tissues. CT,
however, is limited in distinguishing between different soft tissues
that have similar densities (17). CT contrast agents were introduced
in order to improve vascular contrast and to enable better delineation
of soft tissue structures with similar or identical contrast properties.
The ability of the CT to distinguish between different tissues is
based on the fact that different tissues provide different degrees
of X-ray attenuation, according to equation (1):
I ¼ I0eμx (1)
where I0 is the incident X-ray intensity, I is the transmitted X-ray
intensity, x is the thickness of the absorber medium and μ is the
mass attenuation coefﬁcient. The most dominant factor
impacting the mass attenuation coefﬁcient is the photoelectric
effect, which is proportional to the third power of the atomic
number of the material (Z3). Therefore, in order to provide good
contrast in CT images, the key factor in the selection of materials
as CT contrast agents is having a high atomic number.
The high-Z nanoparticle contrast agents could also address
the important issue of relatively high radiation exposure of the
CT. The new generation CT contrast agents that are based on
high atomic number materials such as gold have great potential
not only because the of their ability to produce higher intrinsic
contrast, but even more importantly because of the possibility
of lowering the overall radiation exposure to patients.
Low to medium X-ray photon energy (25–120 keV) is used for
diagnostic radiology, producing signiﬁcant contrast between
bone and other tissues and resulting in high-quality CT images.
However, since most of this energy is being absorbed, it exposes
the patient to a high dose of radiation. As the higher-energy
photons in the energy spectrum produced by the X-ray tubes
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will have a much lower interaction cross section for soft tissue
than the nanoparticles, it is possible that, by ﬁltering the X-ray
spectrum, yielding a lower absorbed radiation dose to the
patient, the uptake pattern of these particles can be visualized
as distinct contrast relative to their soft tissue background (17).
Therefore, high-Z nanoparticles as contrast agents may permit
CT imaging at lower patient doses and with better sensitivity
and good speciﬁcity.
The atomic number of gold (79) is much higher than that of
the currently used CT contrast material – iodine (53), and there-
fore gold can induce stronger X-ray attenuation (18). In addition,
the small size of iodine molecules allows only very short imaging
times owing to rapid clearance by the kidneys. In contrast, GNPs
can be designed so as to overcome biological barriers and to
remain conﬁned to the intravascular space for prolonged times
(19–21). The optimal size (for spherical particles) should be larger
than ~15 nm, so as to avoid rapid clearance by the kidneys or
uptake in the liver, but smaller than ~200 nm to avoid ﬁltration
in the spleen (20).
Other than its high atomic number advantage, gold is consistently
used in various forms for biological applications owing to ease of
fabrication and surface modiﬁcation, as well as gold’s inherent
biological compatibility (1,4,22,23). Using simple wet-laboratory
techniques, gold nanoparticles have been fabricated in a variety of
shapes and sizes, and used as the core or the shell for polymer–
metal (22,23) and metal–metal (24,25) hybrid nanoparticles.
Photosensitizers, dyes, drugs, genetic materials and targeting moie-
ties can all be attached to the gold nanoparticle surface directly, via
amine or thiol groups (23), or indirectly, using a molecule such as
bovine serum albumin (26) or the penta-peptide with the amino
acid sequence CALNN (27).
In many cases gold by itself has served as the photosensitizer.
Consequently, gold nanoparticles have been most frequently
exploited for photothermal therapy, in comparison to options in-
volving other metal, dye–polymer or carbon-based nanoparticles.
The exceptionally high extinction coefﬁcient of gold (1× 1019 M1
cm1 for 20 nm gold nanoparticles) (28) is orders of magnitude
higher than that of strongly absorbing organic dyes (e.g.
Coomassie blue, 4.3× 104 M1 cm1) (29), which makes gold an
ideal photosensitizer. Also, the localized surface plasmon
resonance of gold nanoparticles is highly dependent on the
morphology of the nanoparticles and can be easily tuned during
the fabrication process (28). Typically, the absorption of gold
nanoparticles is tuned to be in the range between 600 and 1000
nm, the so-called therapeutic window in which the interaction of
light with biological tissues is low, that is, attenuation and scatter-
ing effects are at a minimum.
Thesewide applications of GNPs and their potential for clinical im-
plementation have led to substantial research regarding their in vivo
chemical stability (30–32), pharmacokinetics (31), biodistribution
(32–37) and bio-toxicity (31,33,38–41). The well-known biosafety of
gold (42,43), along with the high degree of ﬂexibility in terms of
particles’size, shape and functional groups for coating and targeting,
provide GNPs with high potential to become the next generation
theranostic agents for cancerous diseases.
3. IMAGING APPLICATIONS
Nanoparticle-based CT contrast agents have been suggested for
several medical imaging applications depending on multiple
parameters such as the particles’ size, coating materials and
targeting moieties. These parameters determine not only the
efﬁcacy of the contrast achieved in CT, but also their biodistribution
and clearance mechanisms. Note that for CT imaging the total
amount of gold per unit volume (voxel) is the only important
parameter, regardless of the shape of the particles.
As blood pool contrast agents, GNPs extended the blood
circulation time from several minutes (with the clinically used
iodine compounds) up to 24 h (44) and show stronger X-ray
attenuation than the currently used iodine-based compounds
(under the same clinically relevant conditions) (44,45). By taking
advantage of the progressive permeation through trans-
endothelial pores on tumor blood vessels (the EPR effect), GNPs
of a certain size range can passively accumulate on tumors. This
nonselective ‘passively targeting’ approach was demonstrated
for breast tumor detection in recent study (46). This study
showed signiﬁcant CT contrast enhancement caused by accumu-
lation of nanoparticle contrast agent both within the tumor and
in areas surrounding it.
Conjugation of antibodies, peptides or other ligands onto the
nanoparticle surface produces active targeting agents, which can
selectively accumulate on speciﬁc cells or tissues. Molecularly
targeted nanoparticles reach tumor tissues through the EPR
effect (as in passive targeting). However, the active targeting
has additive values; the nanoparticles home selectively onto spe-
ciﬁc tumors and remain at the tumor site for extended durations,
thereby increasing the local accumulation of the nanoparticles at
sites of interest.
Speciﬁc targeting could be achieved through the conjugation
of nanoparticles to a variety of ligands, including antibodies,
peptides, aptamers or small molecules that possess high afﬁnity
toward unique molecular signatures found on diseased cells,
such as cancer cells. Hainfeld et al. demonstrated molecular
imaging of cancer with actively targeted CT contrast agents
(47). They showed that gold nanoparticles can enhance the
visibility of millimeter-sized human breast tumors in mice, and
that active tumor targeting (with anti-Her2 antibodies) is 1.6-fold
more efﬁcient than passive targeting. They also showed that the
speciﬁc uptake of the targeted gold nanoparticles in the tumor’s
periphery was 22-fold higher than in surrounding muscle tissue.
In another study, Chanda et al. (48) reported enhanced CT
attenuation of bombesin functionalized gold nanoparticles that
selectively targeted cancer receptor sites that are overexpressed
in prostate, breast and small-cell lung carcinoma. Recently,
folic acid-modiﬁed dendrimer-entrapped GNPs have been
suggested as targeted CT contrast agents of human lung adeno-
carcinoma (49). The study showed an increased CT signal in the
tumor site after administration of these nanoparticles, as can
be seen in Fig. 1. It has also been demonstrated in vitro (9,50)
and in vivo (51) that the CT number of molecularly targeted
head and neck cancer is over 5 times higher than the
corresponding CT number of an identical but untargeted
tumor, and that active tumor targeting is more efﬁcient and
speciﬁc than passive targeting (Fig. 2) (51). This speciﬁc inter-
action between antigen and antibody or receptor and its
ligand was shown to be an effective strategy to improve the
amount and residence time of contrast agents in tumors, as
well as to provide speciﬁc molecular knowledge regarding
the ﬁndings. This new approach of molecularly targeted CT
contrast agents has changed the concept of CT from diagno-
sis based on anatomical structures to diagnosis according to
molecular markers.
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4. PHOTOTHERMAL THERAPY WITH
TARGETED GOLD NANOPARTICLES
Photothermal therapy involves the use of light and a photosensi-
tizer to generate heat for therapeutic purposes. In contrast to
conventional photodynamic therapy, PTT does not require the
presence of oxygen, which may be of importance when a tumor
is large enough to have a hypoxic center. This form of therapy
has many clinical applications in which a laser is utilized as the
light source and certain endogenous pigments are exploited as
photosensitizers. In dermatology, the wide use of PTT for the
treatment of several skin diseases is enabled by the overexpression
of certain endogenous pigments by the anomalous or diseased
cells (52–55). Other clinical applications include biostimula-
tion of wound healing (56–58) and the induced coagulation
of blood vessels (55,59,60). On the other hand, nanoparticle
mediated-photothermal therapy enables noninvasive delivery of
exogeneous photosensitizers to cells, for example, to cancer cells,
in high enough concentrations (61). Gold nanoparticle mediated-
photothermal therapy involves the irradiation of a gold nanoparti-
cle to generate localized heat so as to damage a region of interest.
When excited with light at or near the absorption maximum
(typically in the visible or near-IR range), the electrons in the gold
nanoparticle absorb the incoming irradiation and, subsequently,
are excited from the ground state to a higher energy state. Heat
is then produced in the sample through the nonradiative de-
excitation of the electrons from the upper state back to the ground
state. Detailed calculations concerning the time scales and heat
generation involved in the photothermal process have been
previously reported in various works (28,62–64). In order to ensure
effective nanoparticle-mediated photothermal therapy, the
nanoparticles should be: (1) small in size (about 100 nm or less in
diameter) (20); (2) biologically compatible; and (3) have no serious
toxicity. Moreover, the ability to easily add targeting moieties to
the gold nanoparticle surface enables preferential uptake into
themalignant cells, for selective heating of the targeted cells, while
leaving the neighboring cells intact.
Gold nanoparticle-mediated photothermal therapy can enable
extracellular heating of the cells, by attaching them predominantly
Figure 1. Representative axial micro-computed tomography (CT) images of the xenografts SPC-A1 tumor in nude mice before and after injection with
DENP (dendrimer-entrapped gold nanoparticles by different injection routes for 1, 2, 4 and 6 h. The white star in (a) indicates the location of the tumor.
Reprinted with the permission of Wang et al. (49).
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to the target cells’ external membranes, or intracellular heating,
once the nanoparticle has been taken up within the cell.
Successful nanoparticle-mediated photothermal therapy has
been demonstrated with a variety of different types of nano-
particle matrices, encouraging continuous research efforts
and applications (5,65). Nanoparticle-mediated photothermal
therapy is especially well suited for treating cancer owing to
the increased heat sensitivity associated with cancer cells, as
well as a tumor’s inability to efﬁciently dissipate heat as a result
of its poor vasculature networks. Nanoparticle-mediated
photothermal therapy has been used widely as both a primary
mode of treatment as well as a preliminary treatment aimed at
weakening otherwise resistant cells toward treatment with con-
ventional therapies (65,66).
To date, various cancer cell lines, including breast (6),
epithelial (67,68) and colon (2) cancers, have been successfully
treated by gold nanoparticle-mediated photothermal therapy,
both in vitro and in vivo. Studies involving photothermal ther-
apy aimed at antibiotic resistant bacteria (69,70) have also
been reported with positive results. Recently, a study that
builds on work by Qian et al. (71), has successfully achieved
controlled surface engineering of gold nanoparticles, using
multiple ligands [PEG 5K, (RGD)4 and (nuclear localization sig-
nal) NLS (nuclear localization signal) peptides] for efﬁcient de-
livery into cell nuclei (72). Conﬁrmation of such nuclear
delivery is shown in Fig. 3. An added advantage of utilizing
gold nanoparticles is that they can be clearly distinguished
when cells are imaged using electron microscopy, as also dem-
onstrated in Fig. 3. The nanoparticles were then utilized in PTT
studies. One motivation for this study (72) was to investigate
the likely advantages of directly heating the nucleus of cancer
cells, advantages stemming from the fact that the nucleus has
a smaller target volume, a lower heat capacity and an
increased likelihood of causing irreparable damage to the cell’s
DNA. A stark reduction in the survival curves of the cells that
had gold nanoparticle located predominantly in the nucleus,
vs cells that had nanoparticles located predominantly in the
Figure 3. Transmission electron microscopy (TEM) Conﬁrmation of
nuclear delivery. (A) Surface-modiﬁed GNPs inside the cell’s nucleus are
denoted by red circles. Gold nanoparticles located in the cytosol (circled
in green) and within the lysosome/endosome complex (circled in blue)
are also noted. (B) Zoomed-out view of the same cancer cell. (C) Bright
ﬁeld image of cells before they were ﬁxed. Reprinted with the permission
of Curry (72).
Figure 2. In vivo X-ray CT volume-rendered images of (A) a mouse before gold nanoparticle (GNP) injection, (B) a mouse 6 h post-injection of nonspeciﬁc Im-
munoglobulin G (IgG) GNP as a passive targeting experiment, and (C) a mouse 6 h post-injection of anti-epidermal growth factor receptor (EGFR)-coated GNPs
that are speciﬁcally targeted to the Squamous-cell carcinoma (SCC) head and neck tumor. The anti-EGFR targeted GNPs show clear contrast enhancement of the
tumor (C, yellow arrow), which was undetectable without the GNP contrast agents (A, yellow arrow). CT numbers represent the average HU of the whole tumor
area. All scans were performed using a clinical CT at 80 kVp, 500mA s, collimation 0.625 × 64mmand 0.521 pitch size (a 64-detector CT scanner, LightSpeed VCT,
GE Medical Systems). Reprinted with the permission of Reuveni et al. (51).
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cytosol, was observed for cells that were treated under the
same conditions, that is, the same gold nanoparticle concen-
tration and treatment time (72), as shown in Fig. 4.
Another recent study involving both in vitro and in vivo PTT
studies was reported by Yuan et al. (73). They detail the fabrica-
tion of surfactant-free gold nanostars and their use for both
in vitro and in vivo studies of nanoparticle tracking, via plasmon
enhanced two-photon photoluminescence, and for photo-
thermal therapy of breast cancer cells. The 60 nm gold
‘nanostars’ were fabricated using a citrate gold seed-medi-
ated method that produces a high yield in a short prepara-
tion time of 1 min. The resulting nanostars have a core
diameter ranging from 20 to 25 nm, with approximately eight
to 10 protruding branches (Fig. 5). The in vitro studies were
carried out as follows: breast cancer cells were incubated
with 0.2 nM of bare gold nanostars for 1 h, and then treated
using a 980 nm diode laser (15 W cm2, spot size 8 mm2) for
1–5 min. Yuan and his colleagues found that 3 min of treat-
ment yielded successful cell kill, and 5 min of treatment gave
the best results. Control measurements involving cells that
were exposed to the laser, but had not been incubated with
nanostars, show that these cells were still viable after 5 min
of illumination. For the in vivo studies, PEGylated nanostars
were injected into CD-1 nude mice that were previously
implanted with small dorsal window chambers. After 10 min
of PTT, visual conﬁrmation of photo-ablation was indicated
by the release of the gold nanoparticles out of the ruptured
vessels; scarring occurred one week later (Fig. 6).
One major research area aimed at improving gold nano-
particle-mediated photothermal therapy is the utilization of
gold clusters or aggregates (74–77) as the corresponding
maximum absorption is red-shifted toward the near-IR range
of the ‘therapeutic window’, resulting in less concern regard-
ing unwanted interaction with the surrounding healthy
tissues. It should be noted that, despite the multitude of
promising outcomes, the variability among the results has
continued to encourage further studies aimed as elucidating
the mechanisms of heat generation and thermolysis [e.g.
shockwaves, micro- and nano-bubbles and nanoparticle de-
struction (63,76,78)].
5. MULTIFUNCTIONAL APPROACH:
COMBINING THERAPY AND DIAGNOSTICS
(THERANOSTICS)
To illustrate the multifunctional approach, combining both
imaging and therapy (i.e. theranostics), Fig. 6 shows a mouse
model where both the photothermal therapy and optical
imaging/monitoring thereof were performed with the aid of gold
nanoparticles. For larger animals, such optical imaging would not
work, but X-ray-based CT, enhanced by gold nanoparticles, would.
Thus the emphasis here is on the combination of CT and PTT. The
important point is that, for CT enhancement, it does not matter
where in the cells the nanoparticles are located, while this can
make a large difference with respect to PTT. The potential medical
use of gold nanoparticles for ‘theranostics’ (therapy +diagnostics),
Figure 5. The extinction spectra of 0.2 nM nanostars used for in vitro
photothermal therapy (PTT). In deionized water (DI; solid line) the
plasmon peaks at around 890 nm with a small peak around 525 nm. In
Fetal bovine serum (FBS) containing growth medium (dotted line), the
nanostars’ plasmon peak red-shifted and its intensity decreased. TEM im-
age of nanostars (inset). Scale bars, 50 nm. Reprinted with the permission
of Yuan et al. (73).
Figure 4. Viability of cells incubated with 500 pM concentrations of surface-modiﬁed GNPs and then illuminated at 514 nm for 30 min. Note the large
effect of nuclear targeting (with nuclear localization signal (NLS)). All experiments were done in duplicates. Error bars denote standard error in the per-
centage of live cells at a given time point. Reprinted with the permission of Curry (72).
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that is, their utilization for a combination of therapy (PTT) and
imaging/monitoring (CT), is the major message of this review.
6. SUMMARY AND OUTLOOK: IMAGE
GUIDED THERAPY AND SURGERY
The promise of GNPs for optical and photo-acoustic imaging,
including the utilization of nonlinear optics and enhanced Raman
effects, is covered elsewhere (79). To this can be added tumor
visualization and delineation for the surgeon’s eyes, an important
medical need. In addition to such image-guided surgery, one aims
today at image-guided therapy, including image-monitored
therapy (80). The latter has been mainly achieved with the use of
targeted, multifunctional nanoplatforms (81). Notably, CT is still
the most prevalent imaging method, and PTT is a particularly safe
method, especially with the use of double targeting: targeted
GNPs and target-focused photons. This minimizes potential side
effects, owing to both the double targeting and the biocompatibil-
ity of GNPs, that is, their inertness in the dark. The overall result is a
combination, with a high degree of safety, of imaging and therapy.
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